22246-12-4

Basic information

• Product Name: 6-METHOXY-3,4-DIHYDRO-2H-ISOQUINOLIN-1-ONE
• Synonyms: 6-METHOXY-3,4-DIHYDROISOQUINOLIN-1(2H)-ONE;6-METHOXY-3,4-DIHYDRO-2H-ISOQUINOLIN-1-ONE;6-METHOXY-3,4-DIHYDRO-1(2H)-ISOQUINOLINONE;6-METHOXY-3,4-1(1H)-ISOQUINOLINONE;6-Methyl-3,4-dihydroisoquinolin-1(2H)-one;1(2H)-Isoquinolinone, 3,4-dihydro-6-methoxy-;6-(Methyloxy)-3,4-dihydro-1(2H)-isoquinolinone;6-Methoxy-1,2,3,4-tetrahydroisoquinolin-1-one
• CAS NO: 22246-12-4
• Molecular Formula: C₁₀H₁₁NO₂
• Molecular Weight: 177.2
• EINECS: 1308068-626-2
• Product Categories: Quinoline series
• Mol File: 22246-12-4.mol
• Article Data: 49

Chemical Properties

• Melting Point: 136-138℃
• Boiling Point: 439.787 °C at 760 mmHg
• Flash Point: 219.775 °C
• Appearance: /
• Density: 1.159
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.549
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 14.77±0.20(Predicted)
• CAS DataBase Reference: 6-METHOXY-3,4-DIHYDRO-2H-ISOQUINOLIN-1-ONE(CAS DataBase Reference)
• NIST Chemistry Reference: 6-METHOXY-3,4-DIHYDRO-2H-ISOQUINOLIN-1-ONE(22246-12-4)
• EPA Substance Registry System: 6-METHOXY-3,4-DIHYDRO-2H-ISOQUINOLIN-1-ONE(22246-12-4)

Safety Data

• Hazardous Substances Data: 22246-12-4(Hazardous Substances Data)

Usage

General Description

6-Methoxy-3,4-dihydro-2H-isoquinolin-1-one is a chemical compound generally recognized for its role in chemical research and experimentations. It is a derivative of Isoquinoline, an organic compound and a heterocyclic aromatic alkaloid. Owing to its complex structure and properties, it is often utilized in organic chemistry for creating numerous pharmacological substances. However, specific biological activities, safety, and efficacy of 6-Methoxy-3,4-dihydro-2H-isoquinolin-1-one are not comprehensively studied and acknowledged yet, thus handling the compound requires professional skill and care.

InChI:InChI=1/C10H11NO2/c1-13-8-2-3-9-7(6-8)4-5-11-10(9)12/h2-3,6H,4-5H2,1H3,(H,11,12)

Upstream product

• 337913-25-4 phosphorus pentaoxide 
• 5111-70-6 5-methoxy-1-indanone 
• 74-85-1 ethene 
• 1293990-75-6 N-tert-pentanoyloxy-p-methoxybenzamide 
• 2039-67-0 2-(3-methoxyphenyl)-1-ethanamine 
• 1190890-94-8 tert-butyl-N-[(3-methoxyphenyl)ethyl]carbamate 
• 110192-21-7 N-(methoxycarbonyl)-2-(3'-methoxyphenyl)ethylamine 
• 75-09-2 dichloromethane 
• 19924-43-7 3-methoxyphenylacetonitrile 
• 163713-49-3 3-(3-Methoxy-phenyl)-propionyl azide 
• 40478-49-7 3-(3-methoxyphenyl)propanoyl chloride 
• 10516-71-9 3-(3-Methoxy-phenyl)-propionic acid 
• 62334-10-5 1-isocyano-2-(3-methoxyphenyl)ethane 
• 33543-63-4 ethyl-N-<2-(3-methoxyphenyl)ethyl>-carbamate 

Downstream Products

• 860436-57-3 tert-butyl 6-methoxy-3,4-dihydroisoquinoline-2(1H)-carboxylate 
• 921224-62-6 tert-butyl-6-methoxy-7-nitro-3,4-dihydroisoquinoline-2(1H)-carboxylate 
• 844431-53-4 1-[4-(4-cyclohexyl-piperazin-1-yl)-phenyl]-6-methoxy-2-(3-methoxy-phenyl)-1,2,3,4-tetrahydro-isoquinoline 
• 844431-52-3 1-[4-(4-cyclopentyl-piperazin-1-yl)-phenyl]-6-methoxy-2-(3-methoxy-phenyl)-1,2,3,4-tetrahydro-isoquinoline 
• 844431-51-2 1-[4-(4-cyclopropylmethyl-piperazin-1-yl)-phenyl]-6-methoxy-2-(3-methoxy-phenyl)-1,2,3,4-tetrahydro-isoquinoline 
• 844431-50-1 1-[4-(4-isobutyl-piperazin-1-yl)-phenyl]-6-methoxy-2-(3-methoxy-phenyl)-1,2,3,4-tetrahydro-isoquinoline 

Relevant articles and documents

1-[2-(1-Cyclobutylpiperidin-4-yloxy)-6,7-dihydro-4H-thiazolo[5,4-c]pyridin-5-yl]propan-1-one: a Histamine H3 Receptor Inverse Agonist with Efficacy in Animal Models of Cognition

A series of chemical optimizations, which was guided by in vitro affinity at histamine H3 receptor (H3R), modulation of lipophilicity, ADME properties and preclinical efficacy resulted in the identification of 1-[2-(1-cyclobutylpiperidin-4-yloxy)-6,7-dihydro-4H-thiazolo[5,4-c]pyridin-5-yl]propan-1-one (45 e) as a potent and selective (Ki=4.0 nM) H3R inverse agonist. Dipsogenia induced by (R)-α-methylhistamine was dose dependently antagonized by 45 e, confirming its functional antagonism at H3R. It is devoid of hERG and phospholipidosis issues. Compound 45 e has adequate oral exposures and favorable half-life in both rats and dogs. It has demonstrated high receptor occupancy (ED80=0.22 mg/kg) and robust efficacy in object recognition task and, dose dependently increased acetylcholine levels in brain. The sub-therapeutic doses of 45 e in combination with donepezil significantly increased acetylcholine levels. The potent affinity, selectivity, in vivo efficacy and drug like properties together with safety, warrant for further development of this molecule for potential treatment of cognitive disorders associated with Alzheimer's disease.

FLUOROALLYLAMINE DERIVATIVE AND USE THEREOF

The present invention relates to a fluoroallylamine derivative and use thereof. In particular, the present invention relates to a compound as shown in Formula I, a prodrug, an isomer, an isotope-labeled compound, a solvate or a pharmaceutically acceptable salt thereof, which has VAP-1/SSAO inhibitory activity, and can be used for treating a disease associated with VAP-1/SSAO overactivity.

Isoquinolinone derivatives as potent CNS multi-receptor D2/5-HT1A/5-HT2A/5-HT6/5-HT7 agents: Synthesis and pharmacological evaluation

In this study, a series of novel Isoquinolinone derivatives were synthesized as potential multi-target antipsychotics. Among these, compound 13 showed high affinity for dopamine D2 and serotonin 5-HT1A, 5-HT2A, 5-HT6, and 5-HT7 receptors, showed low affinity for off-target receptors (5-HT2C, H1, and α1), and negligible effects on ether-a-gogo-related gene (hERG; i.e., reduced QT interval prolongation). An animal behavioral study revealed that compound 13 reversed APO-induced hyperlocomotion, MK-801-induced hyperactivity, and DOI-induced head twitch. Moreover, compound 13 exhibited a high threshold for acute toxicity, a lack of tendency to induce catalepsy, and did not cause prolactin secretion or weight gain when compared to risperidone. Furthermore, in the forced swim test, tail suspension test, and novel object recognition test, treatment with compound 13 resulted in improvements in depression and cognitive impairment. In addition, compound 13 had a favorable pharmacokinetic profile in rats. Thus, the antipsychotic drug-like effects of compound 13 indicate that it may be useful for developing a novel class of drugs for the treatment of schizophrenia.